Rapidly progressive lung coinfection due to Rhizopus and Scedosporium in a diabetic marijuana smoker

Kanaujia, Rimjhim; Muthu, Valliappan; Rudramurthy, Shivaprakash M; Kaur, Harsimran

doi:10.1016/j.cmi.2022.05.012

Cited by 4 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Importantly, the mAb does not crossreact with unrelated yeasts and moulds of clinical importance including Aspergillus spp., Candida and Cryptococcus spp., Mucorales spp., and species of Fusarium. This high degree of specificity is of critical importance given the occurrence of mixed fungal co-infections in humans [1,19,40,[71][72][73][74].…”

Section: Discussionmentioning

confidence: 99%

A Lateral-Flow Device for the Rapid Detection of Scedosporium Species

Davies,

Thornton

2024

Preprint

View full text Add to dashboard Cite

Scedosporium species are human pathogenic fungi, responsible for chronic, localised, and life-threatening disseminated infections in both immunocompetent and immunocompromised individuals. Diagnosis of Scedosporium infections currently relies on non-specific CT, lengthy and insensitive culture from invasive biopsy, and time-consuming histopathology of tissue samples. At present, there are no rapid antigen tests that detect Scedosporium-specific biomarkers. Here we report the development of a rapid (30 min) and sensitive (pmol/L sensitivity) lateral-flow device (LFD) test, incorporating a Scedosporium-specific IgG1 monoclonal antibody (mAb), HG12, which binds to extracellular polysaccharide (EPS) antigens of between ~15 kDa and 250 kDa secreted during hyphal growth of the pathogens. The test is compatible with human serum, and allows the detection of the Scedosporium species most-frequently reported as agents of human disease (Scedosporium apiospermum, Scedosporium aurantiacum, and Scedosporium boydii), with limits of detection (LOD) of the EPS biomarkers in human serum of ~0.81 ng/mL (S. apiospermum), ~0.94 ng/mL (S. aurantiacum), and ~1.95 ng/mL (S. boydii). The Scedosporium-specific LFD (ScedLFD) test therefore provides a potential novel opportunity for the detection of infections caused by different Scedosporium species.

show abstract

Section: Discussionmentioning

confidence: 99%

A Lateral-Flow Device for the Rapid Detection of Scedosporium Species

Davies,

Thornton

2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Importantly, the mAb does not cross-react with unrelated yeasts and moulds of clinical importance including Aspergillus spp., Candida and Cryptococcus spp., Mucorales spp., and species of Fusarium. This high degree of specificity is of critical importance given the occurrence of mixed fungal co-infections in humans [1,19,40,[71][72][73][74].…”

Section: Discussionmentioning

confidence: 99%

A Lateral-Flow Device for the Rapid Detection of Scedosporium Species

Davies,

Thornton

2024

Diagnostics

View full text Add to dashboard Cite

Scedosporium species are human pathogenic fungi, responsible for chronic, localised, and life-threatening disseminated infections in both immunocompetent and immunocompromised individuals. The diagnosis of Scedosporium infections currently relies on non-specific CT, lengthy and insensitive culture from invasive biopsy, and the time-consuming histopathology of tissue samples. At present, there are no rapid antigen tests that detect Scedosporium-specific biomarkers. Here, we report the development of a rapid (30 min) and sensitive (pmol/L sensitivity) lateral-flow device (LFD) test, incorporating a Scedosporium-specific IgG1 monoclonal antibody (mAb), HG12, which binds to extracellular polysaccharide (EPS) antigens between ~15 kDa and 250 kDa secreted during the hyphal growth of the pathogens. The test is compatible with human serum and allows for the detection of the Scedosporium species most frequently reported as agents of human disease (Scedosporium apiospermum, Scedosporium aurantiacum, and Scedosporium boydii), with limits of detection (LODs) of the EPS biomarkers in human serum of ~0.81 ng/mL (S. apiospermum), ~0.94 ng/mL (S. aurantiacum), and ~1.95 ng/mL (S. boydii). The Scedosporium-specific LFD (ScedLFD) test therefore provides a potential novel opportunity for the detection of infections caused by different Scedosporium species.

show abstract

“…(Arndt et al, 2009;Bergantim et al, 2013;Henn et al, 2014;Obradovic-Tomasev et al, 2014;Pandey et al, 2019;Anita et al, 2021; Bellanger Benhadid-Brahmi et al, 2022;Johnson et al, 2021;Moorthy et al, 2021;Paul et al (2022); Ramıŕez-Hinojosa et al, 2021;Singh et al, 2021;Zayet et al, 2021;Rahna et al, 2022;Suresh et al, 2022;Tabarsi et al, 2022;Teng et al, 2022;Zhan et al, 2022;Murray et al, 2023;Sardeshmukh et al, 2023), Fusarium spp. (De Almeida Junior et al, 2015;Marino et al, 2023), Candida albicans (Obradovic-Tomasev et al, 2014;Pandey et al, 2019;Jawanda et al, 2022), Cryptococcus neoformans (Henn et al, 2014;Gupta et al, 2023), Lomentospora prolificans (Erami et al, 2023), and Scedosporium apiospermum (Shand et al, 2004;Marques et al, 2011;Song et al, 2022;Kanaujia et al, 2023).…”

Section: Discussionunclassified

Development of a monoclonal antibody and a lateral-flow device for the rapid detection of a Mucorales-specific biomarker

Thornton,

Davies,

Dougherty

2023

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Mucoromycosis is a highly aggressive angio-invasive disease of humans caused by fungi in the zygomycete order, Mucorales. While Rhizopus arrhizus is the principal agent of mucoromycosis, other Mucorales fungi including Apophysomyces, Cunninghamella, Lichtheimia, Mucor, Rhizomucor and Syncephalastrum are able to cause life-threatening rhino-orbital-cerebral, pulmonary, gastro-intestinal and necrotising cutaneous infections in humans. Diagnosis of the disease currently relies on non-specific CT, lengthy and insensitive culture from invasive biopsy, and time-consuming histopathology of tissue samples. At present, there are no rapid antigen tests that detect Mucorales-specific biomarkers of infection, and which allow point-of-care diagnosis of mucoromycosis. Here, we report the development of an IgG2b monoclonal antibody (mAb), TG11, which binds to extracellular polysaccharide (EPS) antigens of between 20 kDa and 250 kDa secreted during hyphal growth of Mucorales fungi. The mAb is Mucorales-specific and does not cross-react with other yeasts and molds of clinical importance including Aspergillus, Candida, Cryptococcus, Fusarium, Lomentospora and Scedosporium species. Using the mAb, we have developed a Competitive lateral-flow device that allows rapid (30 min) detection of the EPS biomarker in human serum and bronchoalveolar lavage (BAL), with a limit of detection (LOD) in human serum of ~100 ng/mL serum (~224.7 pmol/L serum). The LFD therefore provides a potential novel opportunity for detection of mucoromycosis caused by different Mucorales species.

show abstract

Rapidly progressive lung coinfection due to Rhizopus and Scedosporium in a diabetic marijuana smoker

Cited by 4 publications

References 4 publications

A Lateral-Flow Device for the Rapid Detection of Scedosporium Species

A Lateral-Flow Device for the Rapid Detection of Scedosporium Species

A Lateral-Flow Device for the Rapid Detection of Scedosporium Species

Development of a monoclonal antibody and a lateral-flow device for the rapid detection of a Mucorales-specific biomarker

Contact Info

Product

Resources

About